Allero Therapeutics SRL
Allero Therapeutics reported total assets of 78,524 € at the end of the 2025 financial year (annual accounts filed with the NBB on 27 Jul 2026).
The score of Allero Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -18 % Total assets -81 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Allero Therapeutics's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 27 Jul 2026
- Year ended 31 Dec 2024filed on 05 Jul 2025
- Year ended 31 Dec 2023filed on 27 Jul 2024
- Year ended 31 Dec 2022filed on 07 Oct 2023
- Year ended 31 Dec 2021filed on 29 Jul 2022
Allero Therapeutics's financial analysis
- Solvency87.2%sector median: 47.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Allero Therapeutics
Allero Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0665.757.817
- VAT number
- BE0665757817
- Peppol
- Registered · 0208:0665757817 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 04 Nov 2016
- Registered office
- 9000 Ghent
- Latest accounts
- 2025 · filed on 27 Jul 2026
- Activity
- Manufacture of medicaments (NACE 21201)
Allero Therapeutics (SRL) has been based in Ghent since 2016, active in: manufacture of medicaments. For 2025, it reports a net loss of 3,030 € and equity of 68,509 €; its revenue is not published. Its solvency stands at 87.2%, above the median of its sector (47.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Allero Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- Building Constructions Services Buying and selling of own real estate Sint-Genesius-Rode · balance sheet 78,524 €
- Arche de VIE Nursing and midwifery activities Asse · balance sheet 78,530 €
- Mens Cura Medical specialists activities Beersel · balance sheet 78,514 €
- Vecubo Manufacture of metal structures and parts of structures Zwevegem · balance sheet 78,534 €
- CIC Manufacture of carpets and rugs Nazareth-De Pinte · balance sheet 78,507 €
- Mind Ally Sports and recreation education Deinze · balance sheet 78,505 €
Frequently asked questions about Allero Therapeutics
What is the revenue of Allero Therapeutics?
Allero Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Allero Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0665757817 for Allero Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0665.757.817.
Where is the registered office of Allero Therapeutics?
According to the CBE register, the registered office of Allero Therapeutics is in 9000 Ghent.
What is the equity of Allero Therapeutics?
At the close of the 2025 financial year, the equity of Allero Therapeutics amounts to 68,509 €, a solvency of 87.2% of total assets.
Who manages Allero Therapeutics?
The register lists 1 active mandates at Allero Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Allero Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →